Delving into the Latest Updates on Chengdu SciMount Pharmatech Co., Ltd. with Synapse

Overview

To evaluate the safety and tolerability of SMP-656 in patients with advanced solid tumors expressing or mutated HER2, and to determine the maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) of SMP-656. To investigate the pharmacokinetic (PK) characteristics of SMP-656, and to evaluate the preliminary anti-tumor activity and immunogenicity of SMP-656.

Start Date27 Dec 2023

Sponsor / Collaborator

Chengdu SciMount Pharmatech Co., Ltd.

NCT05029518 / CompletedPhase 1

A Phase 1, Randomized, Open-Label, Single-Dose, 3-Way Crossover Study to Compare the PK of Two Oral Formulations of SMP-100 and to Evaluate the Effect of Food on the Bioavailability of SMP-100 Tablets in Normal Healthy Volunteers

This is a single center, Phase 1, randomized, open-label, single-dose, 3 treatment, 3-period, 6-sequence, crossover study designed to compare the PK of SMP-100 dissolved in water for oral administration with SMP-100 tablets under fasting conditions, and to evaluate the effect of food on the bioavailability of SMP-100 tablets in healthy subjects.

Start Date09 Sep 2021

Sponsor / Collaborator

Chengdu SciMount Pharmatech Co., Ltd.

NCT04296799 / CompletedPhase 1

Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of SMP-100 in Normal Healthy Volunteers

This will be the first clinical study of oral administration SMP-100 in healthy subjects. The proposed randomized Phase 1 trial is a double-blind, placebo-controlled, single and multiple ascending dose study in approximately 72 healthy male and female subjects.

Start Date25 Jun 2020

Sponsor / Collaborator

Chengdu SciMount Pharmatech Co., Ltd.

100 Clinical Results associated with Chengdu SciMount Pharmatech Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Chengdu SciMount Pharmatech Co., Ltd.

Login to view more data

1

Literatures (Medical) associated with Chengdu SciMount Pharmatech Co., Ltd.

01 Feb 2023·Biophysical Journal

Structural basis for ligand modulation and partial agonism of the 5-HT3R

Article

Author: Filizola, Marta ; Xie, Dejian ; Felt, Kevin C ; Guzzo, Peter R ; Chakrapani, Sudha ; Stauffer, Madeleine ; Huang, Jinkun ; Salas Estrada, Letty Leslie Ann A

100 Deals associated with Chengdu SciMount Pharmatech Co., Ltd.

Login to view more data

100 Translational Medicine associated with Chengdu SciMount Pharmatech Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 19 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

1

Login to view more data